Home > Newsletters > RxTrials Institute Drug Pipeline Alert > VIA Pharmaceuticals Completes Phase II Enrollment
RxTrials Institute Drug Pipeline Alert
May 21, 2008 | Vol. 6 No. 21
VIA Pharmaceuticals Completes Phase II Enrollment
VIA Pharmaceuticals has completed patient enrollment in its acute coronary syndrome study.
The study has enrolled 191 patients in the second of three Phase II trials investigating VIA-2291, the company's candidate for cardiovascular disease.
The candidate is a potent, small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. It is being developed as a once-daily, oral drug to potentially decrease the risk of major adverse cardiac events associated with inflammation, including heart attack and stroke, the company said.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.